<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50183">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785329</url>
  </required_header>
  <id_info>
    <org_study_id>BDR13362</org_study_id>
    <secondary_id>2012-005005-40</secondary_id>
    <secondary_id>U1111-1134-2618</secondary_id>
    <nct_id>NCT01785329</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects</brief_title>
  <official_title>A Randomized Study of the Relative Bioavailability, Pharmacodynamics, Safety of SAR236553 (REGN727) After Single Subcutaneous Administration at 3 Different Injection Sites in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the relative bioavailability of a single subcutaneous dose of alirocumab SAR236553
      (REGN727) administered at 3 different injection sites in healthy subjects.

      Secondary Objectives:

        -  To assess the pharmacodynamic effect of a single subcutaneous dose of alirocumab
           SAR236553 (REGN727) on serum low-density lipoprotein cholesterol and other lipids and
           apolipoproteins.

        -  To assess the safety of a single subcutaneous dose of alirocumab SAR236553 (REGN727).

        -  To assess the immunogenicity of a single subcutaneous dose of alirocumab SAR236553
           (REGN727).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration of the study per subject is about 15 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Assessment of the serum concentrations of alirocumab SAR236553 (REGN727) after a single subcutaneous administration at 3 different injection sites in healthy subjects as a measure of the pharmacokinetics of this investigational medicinal product.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the serum concentrations of low-density lipoprotein cholesterol after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the pharmacodynamic effect of this investigational medicinal product.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the number of subjects with adverse events after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the safety/tolerability of this investigational medicinal product.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the serum concentration of anti-drug antibodies after a single subcutaneous dose of alirocumab SAR236553 (REGN727) as a measure of the immunogenicity of this investigational medicinal product.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) - Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.
alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) - Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) - Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab SAR236553 (REGN727)</intervention_name>
    <description>Pharmaceutical form:Solution for injection Route of administration: Subcutaneous</description>
    <arm_group_label>alirocumab SAR236553 (REGN727) - Dose A</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) - Dose B</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) - Dose C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy subjects.

        Exclusion criteria:

        Healthy subjects with history or presence of clinically relevant illness.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 826001</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 16, 2013</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
